報價延遲最少15分鐘:2025/06/02 07:28 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.21 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.64/-0.82
|
|
企業價值
92.97M
|
| 資產負債 |
|
每股賬面淨值
1.28
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.89M
|
|
每股收益
0.55
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 07:28 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME. |